PURPOSE: Patients receiving pelvic radiation for cervical cancer experience high rates of acute gastrointestinal (GI) toxicity. The association of changes in the gut microbiome with bowel toxicity from radiation is not well characterized. METHODS AND MATERIALS: Thirty-five patients undergoing definitive chemoradiation therapy (CRT) underwent longitudinal sampling (baseline and weeks 1, 3, and 5) of the gut microbiome and prospective assessment of patient-reported GI toxicity. DNA was isolated from stool obtained at rectal examination and analyzed with 16S rRNA sequencing. GI toxicity was assessed with the Expanded Prostate Cancer Index Composite instrument to evaluate frequency, urgency, and discomfort associated with bowel function. Shannon diversity index was used to characterize alpha (within sample) diversity. Weighted UniFrac principle coordinates analysis was used to compare beta (between sample) diversity between samples using permutational multivariate analysis of variance. Linear discriminant analysis effect size highlighted microbial features that best distinguish categorized patient samples. RESULTS: Gut microbiome diversity continuously decreased over the course of CRT, with the largest decrease at week 5. Expanded Prostate Cancer Index Composite bowel function scores also declined over the course of treatment, reflecting increased symptom burden. At all individual time points, higher diversity of the gut microbiome was linearly correlated with better patient-reported GI function, but baseline diversity was not predictive of eventual outcome. Patients with high toxicity demonstrated different compositional changes during CRT in addition to compositional differences in Clostridia species. CONCLUSIONS: Over time, increased radiation toxicity is associated with decreased gut microbiome diversity. Baseline diversity is not predictive of end-of-treatment bowel toxicity, but composition may identify patients at risk for developing high toxicity.
PURPOSE:Patients receiving pelvic radiation for cervical cancer experience high rates of acute gastrointestinal (GI) toxicity. The association of changes in the gut microbiome with bowel toxicity from radiation is not well characterized. METHODS AND MATERIALS: Thirty-five patients undergoing definitive chemoradiation therapy (CRT) underwent longitudinal sampling (baseline and weeks 1, 3, and 5) of the gut microbiome and prospective assessment of patient-reported GI toxicity. DNA was isolated from stool obtained at rectal examination and analyzed with 16S rRNA sequencing. GI toxicity was assessed with the Expanded Prostate Cancer Index Composite instrument to evaluate frequency, urgency, and discomfort associated with bowel function. Shannon diversity index was used to characterize alpha (within sample) diversity. Weighted UniFrac principle coordinates analysis was used to compare beta (between sample) diversity between samples using permutational multivariate analysis of variance. Linear discriminant analysis effect size highlighted microbial features that best distinguish categorized patient samples. RESULTS:Gut microbiome diversity continuously decreased over the course of CRT, with the largest decrease at week 5. Expanded Prostate Cancer Index Composite bowel function scores also declined over the course of treatment, reflecting increased symptom burden. At all individual time points, higher diversity of the gut microbiome was linearly correlated with better patient-reported GI function, but baseline diversity was not predictive of eventual outcome. Patients with high toxicity demonstrated different compositional changes during CRT in addition to compositional differences in Clostridia species. CONCLUSIONS: Over time, increased radiation toxicity is associated with decreased gut microbiome diversity. Baseline diversity is not predictive of end-of-treatment bowel toxicity, but composition may identify patients at risk for developing high toxicity.
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Vancheswaran Gopalakrishnan; Beth A Helmink; Christine N Spencer; Alexandre Reuben; Jennifer A Wargo Journal: Cancer Cell Date: 2018-04-09 Impact factor: 31.743
Authors: Tatiana V Karpinets; Vancheswaran Gopalakrishnan; Jennifer Wargo; Andrew P Futreal; Christopher W Schadt; Jianhua Zhang Journal: Front Microbiol Date: 2018-03-07 Impact factor: 5.640
Authors: Elizabeth M Park; Manoj Chelvanambi; Neal Bhutiani; Guido Kroemer; Laurence Zitvogel; Jennifer A Wargo Journal: Nat Med Date: 2022-04-19 Impact factor: 87.241
Authors: Molly B El Alam; Travis T Sims; Ramez Kouzy; Greyson W G Biegert; Joseph A B I Jaoude; Tatiana V Karpinets; Kyoko Yoshida-Court; Xiaogang Wu; Andrea Y Delgado-Medrano; Melissa P Mezzari; Nadim J Ajami; Travis Solley; Mustapha Ahmed-Kaddar; Lilie L Lin; Lois Ramondetta; Amir Jazaeri; Anuja Jhingran; Patricia J Eifel; Kathleen M Schmeler; Jennifer Wargo; Ann H Klopp; Lauren E Colbert Journal: PLoS One Date: 2021-03-04 Impact factor: 3.240
Authors: Byeongsang Oh; Thomas Eade; Gillian Lamoury; Susan Carroll; Marita Morgia; Andrew Kneebone; George Hruby; Mark Stevens; Frances Boyle; Stephen Clarke; Brian Corless; Mark Molloy; David Rosenthal; Michael Back Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639
Authors: Travis T Sims; Molly B El Alam; Tatiana V Karpinets; Stephanie Dorta-Estremera; Venkatesh L Hegde; Sita Nookala; Kyoko Yoshida-Court; Xiaogang Wu; Greyson W G Biegert; Andrea Y Delgado Medrano; Travis Solley; Mustapha Ahmed-Kaddar; Bhavana V Chapman; K Jagannadha Sastry; Melissa P Mezzari; Joseph F Petrosino; Lilie L Lin; Lois Ramondetta; Anuja Jhingran; Kathleen M Schmeler; Nadim J Ajami; Jennifer Wargo; Lauren E Colbert; Ann H Klopp Journal: Commun Biol Date: 2021-02-22